title: Cabergoline therapy for macroprolactinoma during pregnancy: a case report.
abstract: BACKGROUND
  We assessed the safety of Cabergoline therapy during pregnancy in a lady with hyperprolactinemia intolerant to Bromocriptine.
  
  
  METHODS
  We report the case of a 31 year old lady who presented to us with uncontrolled hyperprolactinemia. A pituitary Macroadenoma was demonstrated by MRI. Due to intolerance to Bromocriptine, Cabergoline was started. The patient improved and subsequently conceived. MRI in the second trimester demonstrated further reduction in the tumor size. It was decided to continue Cabergoline throughout pregnancy to ensure further reduction in tumor size until delivery and to hold Cabergoline during postpartum period to allow for an adequate interval of breastfeeding. At 37 weeks of gestation, the patient delivered a healthy baby.
  
  
  CONCLUSIONS
  We were able to safely treat macroprolactinemia in our patient during pregnancy with cabergoline. This case report contributes to the relatively meager data available which advocates the safety of cabergoline therapy in pregnant hyperprolactinemic patients.
authors.affiliation: Medical College, Aga Khan University Hospital, Karachi, Pakistan. hira_shahzad88@hotmail.com
authors.forename: Hira
authors.initials: H
authors.lastname: Shahzad
authors.forename: Aisha
authors.initials: A
authors.lastname: Sheikh
authors.forename: Lumaan
authors.initials: L
authors.lastname: Sheikh
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077465:Cabergoline; D004873:Ergolines / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D010911:Pituitary Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D011388:Prolactin / Q000037:antagonists & inhibitors / Q000097:blood; D015175:Prolactinoma / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline